INSURANCE/HEALTH: Provides relative to formulary placement and cost-sharing requirements for certain generic drugs and biosimilars (EN NO IMPACT See Note)

Summary

The law defines a drug’s “net cost” after rebates and requires insurers to disclose detailed rebate information for each product. It protects patients who are already taking a reference listed drug by prohibiting insurers from moving the drug to a higher cost tier, raising cost‑sharing, or adding new restrictions unless a doctor agrees or a medical‑necessity exception is granted. The commissioner must publish an annual report on these formulary changes while keeping proprietary data confidential.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share